Table 1.

Utility and limitations of measurements of serum anti‐Müllerian hormone (AMH) levels in various clinical conditions

	What have we learned?	What should we know?
Medically assisted reproduction	Good correlation to oocyte yield Predictive potential for poor and hyper‐response	Predictive potential for live births Optimization of protocols to improve treatment success
General population	Peaks around 25 years of age and gradually declines Very low serum AMH level does not necessarily mean sterility	Predictive potential for future fertility
Menopause/POI	Undetectable serum AMH level is followed by menopause within a certain time period depending on age	Selection and diagnosis of subclinical POI
PCOS	Elevated serum AMH level is correlated with severity	Association with pathophysiology Optimization of treatment schedules according to serum AMH levels
Ovarian toxicity/surgical intervention	Decline depending on chemotherapeutic regimens and surgical interventions, especially cystectomy for endometriomas	Indication of fertility preservation Optimal interventions according to ovarian reserve

POI primary ovarian insufficiency, PCOS polycystic ovary syndrome